Introduction {#jde14706-sec-0001}
============

Psoriasis (PsO) can be defined as a chronic, systemic inflammatory disease that can affect the skin, semi‐mucosa, joints, and additional organs and tissues. Clinical manifestations can be presented as plaques on elbows, knees or scalp and/or superficial pustules on palms, soles or diffused over the body.[1](#jde14706-bib-0001){ref-type="ref"} There are several clinical variations of PsO; psoriasis vulgaris (also known as plaque psoriasis) is the most common (75--90%).[2](#jde14706-bib-0002){ref-type="ref"} Disease prevalence is as high as 11.8% in several reports from different countries.[1](#jde14706-bib-0001){ref-type="ref"}, [3](#jde14706-bib-0003){ref-type="ref"}, [4](#jde14706-bib-0004){ref-type="ref"}, [5](#jde14706-bib-0005){ref-type="ref"}, [6](#jde14706-bib-0006){ref-type="ref"} A recent telephone survey estimates a prevalence of 1.3% in Brazil.[1](#jde14706-bib-0001){ref-type="ref"}, [3](#jde14706-bib-0003){ref-type="ref"}, [4](#jde14706-bib-0004){ref-type="ref"}, [5](#jde14706-bib-0005){ref-type="ref"}, [6](#jde14706-bib-0006){ref-type="ref"}

The pathophysiology of PsO involves an interaction between inflammatory components, elements of the innate and adaptive immune response, and abnormal proliferation and differentiation of keratinocytes.[3](#jde14706-bib-0003){ref-type="ref"} The immune‐mediated feature characterizes PsO as a systemic illness that contributes to a greater frequency of comorbidities among affected subjects.[7](#jde14706-bib-0007){ref-type="ref"}, [8](#jde14706-bib-0008){ref-type="ref"}

Common comorbidities associated with PsO include metabolic syndrome (MetS), psoriatic arthritis (PsA), diabetes, obesity, hypertension and dyslipidemia. The estimated prevalence of MetS described in the general population varies from 0.2% to 43.9%; however, its association with PsO may be approximately fivefold higher, depending on the characteristics of the population studied.[2](#jde14706-bib-0002){ref-type="ref"}, [9](#jde14706-bib-0009){ref-type="ref"}, [10](#jde14706-bib-0010){ref-type="ref"}, [11](#jde14706-bib-0011){ref-type="ref"}, [12](#jde14706-bib-0012){ref-type="ref"}, [13](#jde14706-bib-0013){ref-type="ref"}, [14](#jde14706-bib-0014){ref-type="ref"}, [15](#jde14706-bib-0015){ref-type="ref"}, [16](#jde14706-bib-0016){ref-type="ref"} The prevalence of PsA among patients with plaque psoriasis ranges 5.9--48%, depending on the patient characteristics and criteria used.[17](#jde14706-bib-0017){ref-type="ref"}, [18](#jde14706-bib-0018){ref-type="ref"} The presence of MetS and/or PsA differs according to disease severity.[19](#jde14706-bib-0019){ref-type="ref"}, [20](#jde14706-bib-0020){ref-type="ref"}, [21](#jde14706-bib-0021){ref-type="ref"} Additionally, according to the published work, 8.3%, 18.4%, 19.6% and 20.0% of patients with plaque psoriasis had comorbid diabetes, obesity, hypertension and dyslipidemia, respectively.[22](#jde14706-bib-0022){ref-type="ref"}

There is an increasing interest within the Brazilian research community to identify the comorbidities associated with PsO and understand the effect of the disease on quality of life. However, this subject is still scarcely researched. Thus, the primary objectives of this study were to evaluate the prevalence of MetS and PsA; secondary objectives were to evaluate patient health‐related quality of life (HRQoL) and the prevalence of hypertension, type 2 diabetes mellitus (T2DM), obesity and dyslipidemia among patients with plaque psoriasis.

Methods {#jde14706-sec-0002}
=======

Study design and eligibility criteria {#jde14706-sec-0003}
-------------------------------------

This was a cross‐sectional observational study conducted in nine tertiary centers, located in southeastern, southern and northern Brazilian regions, specializing in PsO treatment, in the following Brazilian cities (with respective states): São Paulo, Santo André and Ribeirão Preto (state of São Paulo); Rio de Janeiro and Niterói (state of Rio de Janeiro); Curitiba (state of Paraná); Porto Alegre (state of Rio Grande do Sul); and Belém (state of Pará). Eligible patients were those diagnosed with plaque psoriasis reported by medical records and aged 18 years and older. Patients unable to provide informed consent and/or answer the interview, with confirmed/suspected pregnancy and/or enrolled in a drug‐interventional study in the past 12 months were excluded.

Data collection {#jde14706-sec-0004}
---------------

Data collection was performed between April 2014 and May 2015 over three study visits within a 30‐day interval between each visit (±10 days).

During visit 1, patients answered a structured interview, which included questions about sociodemographic and disease characteristics, comorbidities and PsO treatment. Additionally, three standardized questionnaires were used to assess HRQoL: Dermatological Life Quality Index (DLQI), 36‐Item Short Form Health Survey (SF‐36) and EuroQol Five‐Dimension Questionnaire Three‐Level version (EQ‐5D‐3L). Dermatologists performed a physical examination of patients, including blood pressure measurements, radiograph of hands, wrists and feet, and laboratory tests. A pregnancy test was required for all women with child‐bearing potential. Disease severity was classified according to Finlay\'s Rule of Tens; patients with a Psoriasis Area and Severity Index (PASI) score of more than 10 and/or DLQI score of more than 10 or body surface area involvement of more than 10% were considered to have severe PsO.[23](#jde14706-bib-0023){ref-type="ref"} Patients not fulfilling this criterion were considered to have mild to moderate PsO.

At visit 2, a rheumatologist performed a physical examination, including blood pressure measurements. According to the rheumatologist evaluation, 24‐h non‐invasive ambulatory blood pressure monitoring (ABPM) was also required. During this visit, specific imaging and laboratory tests were available for rheumatology assessment and a medical diagnosis of PsA was defined during this visit by the study physician.

At visit 3, patients were informed about all tests results and the need for medical follow up. Medical diagnosis of MetS, hypertension, T2DM, dyslipidemia and obesity were defined during this visit by the study physician.

Prevalence of PsA and MetS {#jde14706-sec-0005}
--------------------------

For this study, the diagnosis of new cases of MetS was defined as the presence of three or more characteristics of the modified version of the criteria proposed by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) and described in the first Brazilian Guidelines for Diagnosis and Treatment of Metabolic Syndrome (Table [S1](#jde14706-sup-0001){ref-type="supplementary-material"}).[24](#jde14706-bib-0024){ref-type="ref"} Individuals currently using antihypertensive, lipid‐lowering or antidiabetic drugs were considered to meet the related diagnosis criterion. The new cases diagnosis of PsA was defined as the presence of 3 points or more in the Classification Criteria for Psoriatic Arthritis (CASPAR).[25](#jde14706-bib-0025){ref-type="ref"} The self‐reported diagnosis of MetS and PsA by patients was also considered to identify the presence of these comorbidities.

Prevalence of hypertension, T2DM, obesity and dyslipidemia {#jde14706-sec-0006}
----------------------------------------------------------

Hypertension was diagnosed/defined as any of the following: presence of disease and/or use of antihypertensive medications according to the patient\'s history or medical records; blood pressure of 180 × 110 mmHg or more at visit 1 and/or visit 2; or ABPM results (24‐h, \>125/75 mmHg; awake, \>130/85 mmHg; asleep, \>110/70 mmHg).[26](#jde14706-bib-0026){ref-type="ref"} The diagnosis of T2DM was defined as a confirmed diagnosis of diabetes and/or use of hypoglycemic drugs, according to patient history or medical records or fasting plasma glucose of 126 mg/dL or more, or glycated hemoglobin A1c of 6.5% or more.[27](#jde14706-bib-0027){ref-type="ref"} Obesity was defined as a body mass index of 30 kg/m^2^ or more.[28](#jde14706-bib-0028){ref-type="ref"} Dyslipidemia was identified as the presence of already diagnosed disease and/or the use of lipid‐lowering medications, according to the patient history or medical records, considering the Brazilian Guidelines for Dyslipidemia (low‐density lipoprotein \[LDL\] of ≥160 mg/dL and/or triglycerides of ≥150 mg/dL and/or high‐density lipoprotein \[HDL\] of \<40 mg/dL in men/\<50 mg/dL in women or in association with LDL or triglyceride increase).[24](#jde14706-bib-0024){ref-type="ref"}

Health‐related quality of life {#jde14706-sec-0007}
------------------------------

The DLQI is a quality‐of‐life questionnaire specifically for patients with dermatological conditions, consisting of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships and treatment. The total score is calculated by summing the score of each question, resulting in a maximum score of 30 and a minimum score of 0, with higher scores representing a worsening quality of life.[29](#jde14706-bib-0029){ref-type="ref"}

The SF‐36 is a generic measure of HRQoL, composed of 36 questions grouped into eight health domains (physical functioning, role‐physical, bodily pain, general health, vitality, social functioning, role‐emotional and mental health) that contribute to the calculation of the physical component summary (PCS) and mental component summary (MCS) scores. The raw score of each dimension was derived by summing the item scores and converting the score to a value from 0 (worst possible health state) to 100 (best possible health state).[30](#jde14706-bib-0030){ref-type="ref"}

The EQ‐5D‐3L is a generic instrument that assesses health status through five domains (mobility, self‐care, usual activities, pain/discomfort and anxiety/depression) with three response levels (no problems, some problems and extreme problems). It also includes a visual analog scale, which records respondents' self‐rated health, according to end‐points labeled from best imaginable health state(100 points) to worst imaginable health state (0 points). A utility score is also calculated based on the dimensions scores, using the UK value set, ranging between 0 (representing death) and 1 (representing perfect health).[31](#jde14706-bib-0031){ref-type="ref"}, [32](#jde14706-bib-0032){ref-type="ref"}

All HRQoL instruments applied in this study were previously translated and validated to Brazilian Portuguese.[33](#jde14706-bib-0033){ref-type="ref"}, [34](#jde14706-bib-0034){ref-type="ref"}, [35](#jde14706-bib-0035){ref-type="ref"}

Sample size calculation {#jde14706-sec-0008}
-----------------------

Sample size was calculated according to the study\'s primary objective, considering a PsA prevalence of 20.6%[36](#jde14706-bib-0036){ref-type="ref"} and a MetS prevalence of 17.8%.[37](#jde14706-bib-0037){ref-type="ref"} Samples of 238 and 225 subjects were necessary to estimate the prevalence of PsA and MetS, respectively, with a precision of 0.05 (error, ±0.05). Including a 20% dropout rate, the largest sample size estimation was a total of 298 subjects with plaque psoriasis.

Statistical analysis {#jde14706-sec-0009}
--------------------

Descriptive analysis was performed by estimation of measures of central tendency and dispersion for quantitative variables and frequency for qualitative variables. Logistic regression was used to build a multivariate model to assess factors associated with PsA/MetS, controlled for possible confounders and interactions. Confounders/interactions were identified from inclusion and exclusion of each covariate in the models. In this process, significant changes in respective coefficients were observed, and the possibilities of confounding or interactions were verified. All potential covariates were selected according to their importance as described in the published work. Final model variates were selected from univariate model, according to a significance level of 0.250. A significance level of α = 0.05 was used for confidence interval (CI) calculations and significance testing. Analyses were performed using Stata version MP11 (StataCorp, College Station, TX, USA) and R Project version 2.13.1 (R Foundation, Vienna, Austria).

Ethical approval {#jde14706-sec-0010}
----------------

This study was approved by the independent ethics committees of each participating site: Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo -- HCFMRP‐USP (no. 532.679); Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo--HCFMUSP (no. 706.903); Faculdade de Medicina do ABC--FMABC (no. 676.619); Instituto de Dermatologia e Estética do Brasil Ltda--IDERJ (no. 694.166); Universidade Federal Fluminense -- UFF (no. 783.956); Hospital Universitário Evangélico de Curitiba -- HUEC (no. 725.735); Irmandade da Santa Casa de Misericórdia de Curitiba (no. 680.066); Hospital de Clínicas de Porto Alegre--HCPA (no. 692.687); and Universidade do Estado do Pará -- UEPA (no. 753.414). Written approval was obtained from all respondents before participation in the research.

Results {#jde14706-sec-0011}
=======

Sociodemographic characteristics {#jde14706-sec-0012}
--------------------------------

In Table [1](#jde14706-tbl-0001){ref-type="table"}, several characteristics of the patient population are described. The study enrolled 293 individuals, 51.9% male, with a mean age of 52.0 (standard deviation \[SD\] = 12.8) years. Most patients were Caucasian/white (67.9%). Regarding employment status and education levels, 31.4% of subjects were employed and 28.3% completed high school. Of the total sample, 16.7% were current smokers, 35.8% reported alcohol consumption (of drinkers, 54.3% reported ingesting alcohol \<1/week) and 33.4% were sedentary. According to the Rule of Tens, 83.3% of patients were classified as having severe PsO. In the past 12 months, 97.2% of patients reported the use of one or more drug for PsO treatment and 20.1% used phototherapy. Among patients who reported medication use, 90.2% received topical drugs, 42.1% received conventional systemic drugs and 31.6% received biologic drugs. Only 4.4% of patients had a family history of PsA and 15.7% had a family history of MetS.

###### 

Sociodemographic and clinical characteristics of patients with plaque‐type psoriasis in a Brazilian population (*n* = 293)

  Characteristics                                                                   *n*               \%
  --------------------------------------------------------------------------------- ----------------- ------
  Age                                                                                                 
  Mean ± SD                                                                         52.0 ± 12.8       --
  Sex                                                                                                 
  Male                                                                              152               51.9
  Female                                                                            141               48.1
  Race                                                                                                
  Caucasian/white                                                                   199               67.9
  Brown                                                                             79                27.0
  Black                                                                             13                4.4
  Asian                                                                             1                 0.3
  Indigenous                                                                        1                 0.3
  Educational level                                                                                   
  No education                                                                      3                 1.0
  Incomplete elementary school                                                      75                25.6
  Complete elementary school                                                        33                11.3
  Incomplete high school                                                            31                10.6
  Complete high school                                                              83                28.3
  Incomplete college and/or university degree                                       21                7.2
  Complete college and/or university degree                                         36                12.3
  Post‐graduate                                                                     11                3.7
   Family history                                                                                     
  MetS                                                                              46                15.7
  PsA                                                                               13                4.4
   Employment status                                                                                  
  Employed                                                                          92                31.4
  Retired                                                                           87                29.7
  Autonomous worker                                                                 66                22.5
  Unemployed                                                                        22                7.5
  Housewife                                                                         13                4.4
  Student                                                                           9                 3.1
  Other[†](#jde14706-note-0001){ref-type="fn"}                                      4                 1.4
  Monthly household income (\$US)                                                                     
  Mean ± SD                                                                         774.29 ± 687.85   --
  PASI                                                                                                
  PASI score, mean ± SD                                                             7.3 ± 8.4         --
  PASI score \>10                                                                   219               74.7
  BSA                                                                                                 
  BSA involvement %, mean ±SD                                                       12.7 ± 15.8       --
  BSA involvement \>10                                                              212               72.4
  DLQI score                                                                                          
  DLQI score, mean ± SD                                                             6.5 ± 6.9         --
  DLQI score \>10                                                                   65                22.2
  Severity of psoriasis (defined as Finlay\'s Rule of Tens)                                           
  Severe psoriasis (PASI score \>10 and/or DLQI score \>10 or BSA involved \>10%)   244               83.3
  Mild to moderate psoriasis                                                        49                16.7
  Treatment pattern                                                                                   
  Phototherapy                                                                      59                20.1
  Medicines                                                                         285               97.2
  Biologic                                                                          90                31.6
  Conventional systemic                                                             120               42.1
  Topical                                                                           257               90.2
  Smoking                                                                                             
  Non‐smokers                                                                       131               44.7
  Current                                                                           49                16.7
  Past                                                                              113               38.6
  Length of abstinence in years (*n* = 113), mean ± SD                              15 ± 10.4         --
  No. of cigarettes per day (*n* = 162), mean ± SD                                  19.3 ± 18.5       --
  "How long have you been smoking?", years (*n* = 162), mean ± SD                   22.3 ± 13.9       --
  Alcoholism                                                                                          
  Non‐drinkers                                                                      188               64.2
  Drinkers                                                                          105               35.8
  Frequency of alcohol consumption (*n* = 105)                                                        
  \<1 per week                                                                      57                54.3
  Once per week                                                                     20                19
  Twice per week                                                                    16                15.2
  3 times a week                                                                    5                 4.8
  4 times a week                                                                    1                 1.0
  5 times a week                                                                    1                 1.0
  6 times a week                                                                    1                 1.0
  7 times a week                                                                    3                 2.9
  No information                                                                    1                 1.0
  "How long have you been drinking?", years (*n* = 105), mean ± SD                  28.6 ± 14         --
  Physical activity                                                                                   
  Sedentary                                                                         98                33.4
  Currently physically active                                                       101               34.5
  Physically active in the past                                                     94                32.1
  Time (years) without practicing (*n* = 94), mean ± SD                             7.2 ± 7.8         --
  Frequency of physical activity (*n* = 195)                                                          
  Once per week                                                                     26                13.3
  Twice per week                                                                    39                20
  3 times a week                                                                    47                24.1
  4 times a week                                                                    15                7.7
  5 times a week                                                                    40                20.5
  6 times a week                                                                    5                 2.6
  7 times a week                                                                    23                11.8
  "How long have you been practicing physical activity?", years, mean ± SD          10 ± 12.5         --

^†^Off work (*n* = 2) and pensioner (*n* = 2). BSA, body surface area; DLQI, Dermatology Life Quality Index; MetS, metabolic syndrome; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; SD, standard deviation.

John Wiley & Sons, Ltd

Prevalence of PsA, MetS and related comorbidities {#jde14706-sec-0013}
-------------------------------------------------

The prevalence of PsA was 41.8% (95% CI, 36.0--47.6) in patients who fulfilled CASPAR (35.7%) and/or had reported a medical history of PsA (23.1%). Of the total number of patients with a PsA diagnosis, new cases accounted for 44.9% (53/118). Considering only CASPAR (*n* = 100), the estimated proportion of newly diagnosed cases represented 53.0% of patients diagnosed using these criteria (Table [2](#jde14706-tbl-0002){ref-type="table"}), and all of these patients presented with a current/personal history/family history of PsO and inflammatory articular disease. For the other CASPAR items, 86.0% had a negative test for rheumatoid factor, 79.0% had radiological evidence of juxta‐articular new bone formation, 61.0% had psoriatic nail dystrophy and 22.0% had dactylitis (current or history).

###### 

Prevalence of PsA and MetS among patients with plaque‐type psoriasis in a Brazilian population (*n* = 282)

  Comorbidity                                                             Diagnostic categories                                 *n*    \%           95% CI
  ----------------------------------------------------------------------- ----------------------------------------------------- ------ ------------ ------------
  Psoriatic arthritis                                                     History of PsA reported by the patient (*n* = 282)    65     23.1         30.1--41.3
  PsA diagnosed by the study physician, CASPAR (*n* = 282)                100                                                   35.7   37.2--56.8   
  Previous diagnosis among CASPAR‐positive patients (*n* = 100)           47                                                    47.0   43.2--62.8   
  Newly diagnosed among CASPAR‐positive patients (*n* = 100)              53                                                    53.0   18.2--28.0   
  Final prevalence of PsA (CASPAR or history) (*n* = 282)                 118                                                   41.8   36.0--47.6   
  Metabolic syndrome                                                      History of MetS reported by the patient (*n* = 282)   17     6.0          3.2--8.8
  Diagnosis confirmed by the physician (*n* = 282)                        137                                                   48.6   42.8--54.4   
  Patients newly diagnosed in the study (*n* = 141)                       107                                                   75.9   68.8--83.0   
  Final prevalence of MetS (physician diagnosis or history) (*n* = 282)   141                                                   50.0   44.2--55.8   

CASPAR, Classification Criteria for Psoriatic Arthritis; CI, confidence interval; MetS, metabolic syndrome; PsA, psoriatic arthritis.

John Wiley & Sons, Ltd

The prevalence of MetS was 50.0%; 75.9% were newly diagnosed in the study. Considering the modified version of NCEP ATP III criteria (*n* = 138), 88.4% had a fasting blood glucose level of 110 mg/dL or more, and/or history of T2DM and/or use of antidiabetic drugs; 81.2% had HDL of less than 40 mg/dL (males) or less than 50 mg/dL (females); 77.5% had a waist circumference of more than 102 cm (males) or more than 88 cm (females); 63.8% had triglycerides of 150 mg/dL or more; and 56.5% had blood pressure of 130 × 85 mmHg or more, and/or a history of systemic arterial hypertension and/or use of antihypertensive drugs.

As assessed by secondary outcomes, the estimated prevalence of comorbidities is shown in Figure [1](#jde14706-fig-0001){ref-type="fig"}. Dyslipidemia was the most prevalent comorbidity (74.5%), followed by hypertension (61.8%), obesity (52.5%) and T2DM (30.9%).

![Prevalence of comorbidities assessed as secondary outcomes among patients with plaque‐type psoriasis.](JDE-46-3-g001){#jde14706-fig-0001}

Health‐related quality of life {#jde14706-sec-0014}
------------------------------

Data regarding HRQoL are shown in Table [3](#jde14706-tbl-0003){ref-type="table"}. The DLQI mean score was 6.5 (SD = 6.9). According to questionnaire\'s dimensions, the greatest impact was noted in symptoms and feelings (mean = 2.1; SD = 1.7). Nevertheless, all dimensions presented less than half of the maximum value for each dimension, indicating impairment of patients' HRQoL. Regarding DLQI categories, the quality of life of a majority of patients (70.2%) was affected, considering the summation of the answers that represents some effect on the patient\'s life (whether small, moderate, very or extreme; Fig. [2](#jde14706-fig-0002){ref-type="fig"}).

###### 

Quality‐of‐life scores on each scale, using DLQI, SF‐36 and EQ‐5D‐3L questionnaires among patients with plaque‐type psoriasis in a Brazilian population

  HRQoL measure                               Dimension                             Mean   SD
  ------------------------------------------- ------------------------------------- ------ ------
  DLQI (*n* = 292)                            Symptoms and feelings (maximum = 6)   2.1    1.7
  Daily activities (maximum = 6)              1.5                                   1.8    
  Leisure (maximum = 6)                       1.3                                   1.7    
  Personal relationships (maximum = 6)        0.8                                   1.5    
  Work and school (maximum = 3)               0.4                                   0.8    
  Treatment (maximum = 3)                     0.4                                   0.7    
  Total (maximum = 30)                        6.5                                   6.9    
  SF‐36 (*n* = 292)                           Vitality (0--100)                     50.6   11.2
  General health (0--100)                     45.1                                  11.0   
  Role‐physical (0--100)                      44.8                                  11.8   
  Social functioning (0--100)                 44.4                                  12.3   
  Mental health (0--100)                      44.1                                  12.8   
  Physical functioning (0--100)               44.0                                  11.4   
  Bodily pain (0--100)                        43.9                                  11.6   
  Role‐emotional (0--100)                     43.5                                  12.6   
  Physical component summary score (0--100)   45.2                                  10.4   
  Mental component summary score (0--100)     45.5                                  12.3   
  EQ‐5D‐3L (*n* = 286)                        Utility score (0--1)                  0.68   0.27
  Overall value (0--100)                      72.7                                  19.7   

DLQI, Dermatology Life Quality Index; EQ‐5D‐3L, EuroQol Five‐Dimension Questionnaire Three‐Level version; SD, standard deviation; SF‐36, 36‐Item Short Form Health Survey.

John Wiley & Sons, Ltd

![Impairment in health status according to the Dermatology Life Quality Index classification among patients with plaque psoriasis (*n* = 292).](JDE-46-3-g002){#jde14706-fig-0002}

According to SF‐36 results, the most impaired scales were role‐emotional (mean = 43.5; SD = 12.6) and bodily pain (mean = 43.9; SD = 11.6). For the EQ‐5D‐3L instrument, the mean utility index was 0.68 (SD = 0.27); the mean EQ‐5D‐3L visual analog scale was 72.7 (SD = 19.7). Among the five dimensions, self‐care was the least affected, with 84.6% of the responders reporting an absence of problems. The highest impairment was observed for the dimension of pain and discomfort (66.4% of patients reported to have problems, some problems or extreme). Extreme problems were more frequently reported in the dimension of anxiety and depression (9.4%; Fig. [3](#jde14706-fig-0003){ref-type="fig"}).

![Limitations in health‐related quality of life in each dimension of the EuroQol Five‐Dimension Questionnaire Three‐Level version questionnaire among patients with plaque‐type psoriasis (*n* = 286).](JDE-46-3-g003){#jde14706-fig-0003}

Logistic regression models {#jde14706-sec-0015}
--------------------------

In the present study, multivariate models were used to assess factors associated with the presence of PsA and MetS among plaque psoriasis patients (Tables [S2](#jde14706-sup-0001){ref-type="supplementary-material"},[S3](#jde14706-sup-0001){ref-type="supplementary-material"}). A multivariate model for PsA (adjusted by use of topical drugs and phototherapy and frequency of alcohol consumption) showed that a greater odds of PsA diagnosis was associated with treatment with biologic drugs (odds ratio \[OR\] = 3.49; 95% CI, 1.91--6.38; *P* \< 0.001) and conventional systemic medicines (OR = 2.41; 95% CI, 1.4--4.16; *P* = 0.002); conversely, a higher SF‐36 PCS was associated with a decreased odds of PsA diagnosis (OR = 0.96; 95% CI = 0.93--0.99; *P* = 0.002).

For MetS, the final model (adjusted by severe PsO, PsA, use of conventional systemic drugs, alcohol consumption, frequency of smoking and EQ‐5D‐3L) indicated that patients with a family history of MetS had a greater odds of having MetS compared with those without a family history (OR = 2.28; 95% CI, 1.35--3.87; *P* = 0.002); the use of phototherapy (OR = 0.51; 95% CI, 0.26--0.98; *P* = 0.045) and an increase in SF‐36 PCS (OR = 0.96; 95% CI, 0.93--0.99; *P* = 0.015) were negatively associated.

Discussion {#jde14706-sec-0016}
==========

Psoriatic arthritis and MetS are common comorbidities of patients with PsO; however, their frequency present a great variation across subpopulations. Thus, there is a need to understand the prevalence of these conditions in patients with plaque psoriasis to establish proper therapeutic management and reinforce the need for comprehensive guidelines addressing comorbidities.

This study demonstrated that the prevalence of PsA findings among Brazilian patients with PsO is in agreement with other investigations performed in Brazilian cohorts. Carneiro *et al*.[38](#jde14706-bib-0038){ref-type="ref"}, [39](#jde14706-bib-0039){ref-type="ref"} and Ranza *et al*.[38](#jde14706-bib-0038){ref-type="ref"}, [39](#jde14706-bib-0039){ref-type="ref"} reported PsA prevalence of 35.0% and 33.3%, respectively, using CASPAR. The aforementioned studies included patients with all types of PsO and both studies reported a high prevalence of plaque‐type psoriasis (66.9--78.8%). Therefore, these analyses had populations similar to the sample of the present study.

The results of our study also showed that of 118 prevalent cases of PsA, 44.9% were newly diagnosed by the study rheumatologist. This is consistent with the results reported in Ranza *et al*. (49.0%)[39](#jde14706-bib-0039){ref-type="ref"} that highlighted the frequency of undiagnosed cases. Some authors feel that the diagnosis of PsA should be facilitated by dermatologists, as underdiagnosis may lead to potentially avoidable joint damage that permanently disables and deforms some individuals.[40](#jde14706-bib-0040){ref-type="ref"}

To our knowledge, to date, this is the first multicenter study conducted in Brazil that reports the prevalence of MetS in a population of patients with PsO. The prevalence of MetS in the present study was 50.0%. A single center study carried out by Baeta *et al*.[41](#jde14706-bib-0041){ref-type="ref"} in the southeastern region of Brazil (*n* = 190 patients with PsO) observed a 44.9% prevalence of MetS, similar to our study. A case--control Brazilian study investigated research questions similar to ours regarding PsO comorbidities, specifically, the frequency of hypertension and MetS. Our findings were similar to the ones described by Menegon *et al*.[42](#jde14706-bib-0042){ref-type="ref"} regarding both the proportion of patients with MetS (47.1%) and the frequency of hypertension (57.7%). The prevalence of MetS in Brazilian patients with PsO reported in the present study was far higher than in the general Brazilian population (29.6%, ranging 14.9--65.3%).[43](#jde14706-bib-0043){ref-type="ref"} This finding is probably indicative of the mean age of our sample (52.0 years; SD = 12.8), as older age contributes to the higher prevalence of diabetes and hypertension.

Regarding HRQoL, DLQI values are slightly lower than those reported in previous research.[44](#jde14706-bib-0044){ref-type="ref"}, [45](#jde14706-bib-0045){ref-type="ref"}, [46](#jde14706-bib-0046){ref-type="ref"} This may be because a significant percentage of our sample received systemic and biologic drugs, treatments that are associated with a positive impact on HRQoL. Tejada *et al*.[47](#jde14706-bib-0047){ref-type="ref"} have pointed out that PsO is the skin disease with the highest DLQI scores and, therefore, one of the most damaging dermatological illnesses, which highlights the importance of effective treatment options. The SF‐36 PCS (mean = 45.2; SD = 10.4) and MCS (mean = 45.5; SD = 12.3) central tendency measures for our cohort were worse than in the general Brazilian population (mean PCS = 49.3; 95% CI, 49.1--49.5; mean MCS = 51.1; 95% CI, 50.9--51.3).[48](#jde14706-bib-0048){ref-type="ref"} However, considering the high SD, the central tendency measures may vary between better and worse than measures of the general Brazilian population. The multivariate analysis showed that a high PCS is inversely associated with the presence of MetS and PsA, indicating that patients that do not have these comorbidities likely have better HRQoL related to physical aspects. The EQ‐5D‐3L utility index among our sample was 0.68 (SD = 0.27), which is in consonance with other investigations performed in patients with PsO, ranging 0.52 to 0.90.[44](#jde14706-bib-0044){ref-type="ref"}, [49](#jde14706-bib-0049){ref-type="ref"}

Results from the DLQI, SF‐36 and EQ‐5D‐3L showed the impact of the disease on patients' emotional aspects. The most affected DLQI domain in this PsO cohort was symptoms and feelings. This pattern was similarly seen in other studies performed in patients with dermatological conditions.[47](#jde14706-bib-0047){ref-type="ref"}, [50](#jde14706-bib-0050){ref-type="ref"} Similarly, role‐emotional was the most impaired SF‐36 domain in the study participants, followed by bodily pain. The mean SF‐36 scores for role‐emotional and bodily pain in our sample were 43.5 (SD = 12.6) and 43.9 (SD = 11.6), which were much lower than the mean scores for these domains in the general Brazilian population (81.7 and 76.7, respectively).[48](#jde14706-bib-0048){ref-type="ref"} The results of the EQ‐5D‐3L showed that the most affected dimensions of patients' well‐being were those referring to pain and discomfort and anxiety/depression. Our results emphasize the role played by emotional aspects in the quality of life of patients with PsO, endorsing the argument that skin diseases frequently invoke strong negative emotions such as frustration and embarrassment as a reflection that the skin is responsible in large part for an individual\'s appearance.

The study\'s main limitation is the impossibility of establishing a temporal relationship between exposure and outcome due to its cross‐sectional nature; nonetheless, it still provides useful information worthy of exploring in further prospective studies. A certain degree of caution is required concerning the transferability of the results for the whole country, because Brazil is a continent‐sized country marked by considerable environmental and genetic differences, and the northeastern and mid‐west regions were not included. Furthermore, it is important to underscore that the study patients are from tertiary care centers; consequently, those subjects tend to have more severe cases, contributing to a higher prevalence of comorbidities. There are also limitations regarding the understanding of the disease scenario in other levels of care, particularly for patients presenting with milder forms of PsO.

The results of this study firmly establish that MetS and PsA are extremely prevalent among patients with plaque psoriasis. These findings emphasize the relevance of diagnosis and treatment of patients with PsO beyond the care of skin lesions. Cooperation between rheumatologists and dermatologists for the early detection of these comorbidities is crucial.

Patients with plaque psoriasis have a reduced quality of life mainly in terms of emotional aspects, which reinforces the existing data regarding feelings of stigmatization in patients with PsO. It also indicates the relevance of HRQoL measures for patients with plaque psoriasis, already incorporated in Brazilian clinical practise. Physicians should routinely use HRQoL scores to assess patient response to treatment in a more comprehensive way.
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